Hjem
Genetikkgruppen

Varselmelding

There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there
Basic and clinical psychopharmacology

Vidar's Projects

vidar

Hovedinnhold

Psychopharmacology of psychosis – biological mechanisms and animal models

The research group explores how psychopharmacological drugs work in the treatment of psychotic disorders, using a combination of clinical data, biomarker screening and functional studies in experimental models.

 

 

Research focus

At present, our main focus is directed towards the role of lipogenic actions of antipsychotic drugs for adverse effects and treatment response. The apparent correlation between drug-induced metabolic effects (e.g., weight gain and lipid disturbances) and positive clinical outcome during antipsychotic treatment deserves further examination. We are also interested in exploring how changes in brain myelination may provide a link between risk for schizophrenia and the mechanism of action of antipsychotic drugs.

  • Examining the possible relationship between metabolic factors and clinical outcome in antipsychotic-treated patients, including clinical samples with first episode psychosis and drug naiive patients
  • Screening for metabolomic and transcriptomic changes during psychopharmacological treatment, using both cross sectional and longitudinal clinical samples with matched controls.
  • Studying the metabolic effect of antipsychotic drugs in experimental models, including long-term exposure (> one year) in rat.

In addition, we participate in several projects to identify genetic risk factors for disease susceptibility and psychosis-relevant phenotypic traits.

The research group is also responsible for running the Genomics Core Facility at the University of Bergen, to provide guidance and service on large scale genomic analyses, such as whole genome-, exome- and RNA sequencing.

 

Collaboration

We are part of the K.G. Jebsen Center for Psychosis Research, headed by Ole A. Andreassen. Clinical and biological data are available in NORMENT (the TOP sample) and also though our close affiliation with Bergen Psychosis Project 2 (headed by Erik Johnsen). We have specific project collaborations with groups at Karolinska Instition in Stockholm, Sweden, and at the University of Santiago di Compostella in Spain, and we participate in international GWAS consortia.

 

 

 Lab Members

  1. Vidar Martin Steen, Professor
  2. Rita Holdhus, Head Engineer
  3. Anja Torsvik, Post-doc
  4. Hans-Richard Brattbakk, Head Engineer
  5. Tomasz Stokowy, Senior Engineer
  6. Andrea Trentani , Staff Engineer
  7. Aashish Srivastava, Senior Engineer

Funding

The research is funded by the Research Council of Norway, Helse Vest RHF, University of Bergen, Bergen Research Foundation (BFS), Haukeland University Hospital and Dr. Einar Martens Foundation.

 Contact Info